

Highlights of This Issue 2503

SPECIAL FEATURES


CCR Translations

- 2505** Minimal Residual Disease in Breast Cancer: In Blood Veritas
Giulia Siravegna and Alberto Bardelli
See related article, p. 2643

Molecular Pathways

- 2508** Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer
Alastair M. Thompson
- 2516** Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer
Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski, and Lee M. Graves

CCR Focus

- 2524** The Language of Pharmacodynamics
Susan E. Bates
- 2525** Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine
William Douglas Figg and David R. Newell
- 2530** Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology
Daniel L. Hertz and Howard L. McLeod
- 2541** Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics
Siew-Kee Low, Atsushi Takahashi, Taisei Mushiroda, and Michiaki Kubo
- 2553** Circulating Tumor Cells: A Multifunctional Biomarker
 Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, and Johann S. de Bono

- 2569** *In Vivo* Imaging as a Pharmacodynamic Marker
Astrid A.M. van der Veldt and Adriaan A. Lammertsma

- 2578** Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations
Robert Kinders, Kate Ferry-Galow, Lihua Wang, Apurva K. Srivastava, Jiuping (Jay) Ji, and Ralph E. Parchment

- 2587** Pharmacodynamic Biomarkers: Falling Short of the Mark?
Justin F. Gainor, Dan L. Longo, and Bruce A. Chabner

HUMAN CANCER BIOLOGY

- 2595** FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression
Jiujie Cui, Min Shi, Dacheng Xie, Daoyan Wei, Zhiliang Jia, Shaojiang Zheng, Yong Gao, Suyun Huang, and Keping Xie

- 2607** Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
Edmund K. Bartlett, Patricia A. Fetsch, Armando C. Filie, Andrea Abati, Seth M. Steinberg, John R. Wunderlich, Donald E. White, Daniel J. Stephens, Francesco M. Marincola, Steven A. Rosenberg, and Udai S. Kammula

- 2617** miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
Xuanyu Chen, Xuegang Wang, Anming Ruan, Weiwei Han, Yan Zhao, Xing Lu, Pei Xiao, Hangchuan Shi, Rong Wang, Li Chen, Shaoyong Chen, Quansheng Du, Hongmei Yang, and Xiaoping Zhang


- 2631** Regulation of Colorectal Carcinoma Stemness, Growth, and Metastasis by an miR-200c-Sox2–Negative Feedback Loop Mechanism
 Yan-Xia Lu, Li Yuan, Xiao-Lei Xue, Min Zhou, Yan Liu, Chao Zhang, Jing-Ping Li, Lin Zheng, Min Hong, and Xue-Nong Li

Table of Contents

- 2643** **Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer**
Julia A. Beaver, Danijela Jelovac, Sasidharan Balukrishna, Rory L. Cochran, Sarah Croessmann, Daniel J. Zabransky, Hong Yuen Wong, Patricia Valda Toro, Justin Cidado, Brian G. Blair, David Chu, Timothy Burns, Michaela J. Higgins, Vered Stearns, Lisa Jacobs, Mehran Habibi, Julie Lange, Paula J. Hurley, Josh Lauring, Dustin A. VanDenBerg, Jill Kessler, Stacie Jeter, Michael L. Samuels, Dianna Maar, Leslie Cope, Ashley Cimino-Mathews, Pedram Argani, Antonio C. Wolff, and Ben Ho Park
See related article, p. 2505

CANCER THERAPY: PRECLINICAL

- 2651** **Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance—Implications for IGF-II and IGF-IR–Targeted Therapy**
Bin Li, Sai Wah Tsao, Kwok Wah Chan, Dale L. Ludwig, Ruslan Novosyadlyy, Yuk Yin Li, Qing Yu He, and Annie L.M. Cheung
- 2663** **COX-2–Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis**
Anne-Sophie Gallouet, Marion Travert, Laurence Bresson-Bepoldin, Fabien Guilloton, Céline Pangault, Sylvie Caulet-Maugendre, Thierry Lamy, Karin Tarte, and Thierry Guillaudeux
- 2674** **Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth *In Vitro* and *In Vivo***
 Yansheng Hao, Bjoern Chapuy, Stefano Monti, Heather H. Sun, Scott J. Rodig, and Margaret A. Shipp
- 2684** **Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells**
Smita K. Nair, Gabriel De Leon, David Boczkowski, Robert Schmittling, Weihua Xie, Janet Staats, Rebecca Liu, Laura A. Johnson, Kent Weinhold, Gary E. Archer, John H. Sampson, and Duane A. Mitchell

- 2695** **Anti-VEGF Antibodies Mitigate the Development of Radiation Necrosis in Mouse Brain**
Xiaoyu Jiang, John A. Engelbach, Liya Yuan, Jeremy Cates, Feng Gao, Robert E. Drzymala, Dennis E. Hallahan, Keith M. Rich, Robert E. Schmidt, Joseph J.H. Ackerman, and Joel R. Garbow

- 2703** **ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy**
Fan Lin, Mark C. de Gooijer, Eloy Moreno Roig, Levi C.M. Buil, Susan M. Christner, Jan H. Beumer, Thomas Würdinger, Jos H. Beijnen, and Olaf van Tellingen

- 2714** **Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells *In Vitro* and *In Vivo* through Inhibition of IL-6 Signaling and EMT Reversal**
Li Li, Rui Han, Hualiang Xiao, Caiyu Lin, Yubo Wang, Hao Liu, Kunlin Li, Hengyi Chen, Fenfen Sun, Zhenzhou Yang, Jianxin Jiang, and Yong He

- 2727** **Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner**
Diane Palmieri, Renata Duchnowska, Stephan Woditschka, Emily Hua, Yongzhen Qian, Wojciech Biernat, Katarzyna Sosiska-Mielcarek, Brunilde Gril, Andreas M. Stark, Stephen M. Hewitt, David J. Liewehr, Seth M. Steinberg, Jacek Jassem, and Patricia S. Steeg

- 2740** **Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer**
Ju-Won Roh, Jie Huang, Wei Hu, XiaoYun Yang, Nicholas B. Jennings, Vasudha Sehgal, Bo Hwa Sohn, Hee Dong Han, Sun Joo Lee, Duangmani Thanappapasr, Justin Bottsford-Miller, Behrouz Zand, Heather J. Dalton, Rebecca A. Previs, Ashley N. Davis, Koji Matsuo, Ju-Seog Lee, Prahlad Ram, Robert L. Coleman, and Anil K. Sood

IMAGING, DIAGNOSIS, PROGNOSIS

- 2751** **Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume**
Andrea G. Rockall, Norbert Avril, Raymond Lam, Robert Iannone, P. David Mozley, Christine Parkinson, Donald Bergstrom, Evis Sala, Shah-Jalal Sarker, Iain A. McNeish, and James D. Brenton

Table of Contents

- 2761** A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
Rita A. Busuttill, Joshy George, Richard W. Tothill, Kylie Ioculano, Adam Kowalczyk, Catherine Mitchell, Stephen Lade, Patrick Tan, Izhak Haviv, and Alex Boussioutas

- 2773** *In Situ* Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai, and David L. Rimm

CANCER THERAPY: CLINICAL

- 2783** Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing
David C. Turner, Fariba Navid, Najat C. Daw, Shenghua Mao, Jianrong Wu, Victor M. Santana, Michael Neel, Bhaskar Rao, Jennifer Reikes Willert, David M. Loeb, K. Elaine Harstead, Stacy L. Throm, Burgess B. Freeman III, and Clinton F. Stewart

- 2793** A Pharmacodynamic/Pharmacokinetic Study of Ficlatazumab in Patients with Advanced Solid Tumors and Liver Metastases
Josep Tabernero, Maria Elena Elez, Maria Herranz, Isabel Rico, Ludmila Prudkin, Jordi Andreu, Jose Mateos, Maria Josep Carreras, May Han, James Gifford, Marc Credi, Wei Yin, Shefali Agarwal, Philip Komarnitsky, and Jose Baselga

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

- 2805** Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff
Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Mojgan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumiła Czartoryska-Arlukowicz, Piotr J. Wysocki, Małgorzata Foszczyńska-Kłoda, Barbara Radecka, Maria M. Litwiniuk, Jolanta Żok, Michał Wiśniewski, Dorota Zuziak, Wojciech Biernat, and Jacek Jassem


 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a brain section from a mouse injected with a brain seeking variant of the human breast cancer cell line MDA-MB-231. Immunohistochemical staining indicates a lack of MGMT expression in the tumor cells. Tissue was stained with anti-MGMT antibody and counterstained with hematoxylin and eosin. For details, see the article by Palmieri and colleagues on page 2727 of this issue.



Clinical Cancer Research

20 (10)

Clin Cancer Res 2014;20:2503-2813.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/20/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/20/10>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.